AI-Driven Drug Discovery: 10 European Companies to Know in 2026

AI drug discovery has moved beyond whether algorithms can generate plausible molecules. The more important question in 2026 is whether those molecules, targets and biological hypotheses can withstand experimental validation, development decisions and clinical testing.

That distinction shapes this article. A partnership is not proof that a platform works. A clinical candidate is not proof that AI caused its discovery. And clinical entry is not clinical evidence. What matters is the quality of evidence at each stage.

Industry reporting points to more than 170 AI-discovered programmes in clinical development globally. Europe is producing a significant share of the companies working across structural biology, generative chemistry, precision medicine, protein engineering, biologics data infrastructure, cell simulation and industrialised discovery.

Companies were included only if they met most of the following criteria:

• European origin or a meaningful European headquarters and operating base.

• Proprietary AI, machine learning, generative design, computational biology or multimodal data capability applied to real drug discovery problems.

• Evidence of drug candidates, validated targets, discovery programmes, licensing deals or pharmaceutical partnerships.

• Meaningful 2025 or 2026 developments verified through company announcements, ClinicalTrials.gov, CTIS, EMA, FDA or primary press releases.

This is not a funding ranking. Companies are included because they represent a distinct part of the discovery value chain and because their most recent evidence supports the claim being made about them.

A note on Exscientia: it is not featured because Recursion completed its acquisition in November 2024. Exscientia ceased to operate as an independent European company, and Recursion later sold Exscientia GmbH, its Austrian operations, to Alpha Biotechnology GmbH.

Isomorphic Labs is an AI-first drug design company spun out of Google DeepMind. Its Drug Design Engine, IsoDDE, applies AI-based structural and molecular design to small-molecule and biologics discovery.

Focus: Isomorphic uses AI to explore chemical space and design candidates against disease targets. Partners provide biological expertise and lead experimental validation and development.

2026 development: In May 2026, Isomorphic raised $2.1 billion in Series B funding to scale IsoDDE and progress its pipeline towards the clinic. It also announced a cross-modality, multi-target research collaboration with Johnson & Johnson in January 2026, adding to existing collaborations with Eli Lilly and Novartis.

What this tells us: Major pharmaceutical companies are investing in AI-first structural biology at scale. But Isomorphic’s own materials describe its pipeline as progressing towards clinical development, not yet producing approved medicines. The next test is whether its designed candidates generate credible clinical data.

Aqemia is a Paris-based drug invention company applying generative AI and quantum-inspired physics to small-molecule discovery through its Qemi platform.

Focus: Aqemia designs small molecules in chemical space where historical compound data is limited. Pharmaceutical partners validate candidates experimentally and lead development.

2026 development: Sanofi expanded its multi-year collaboration with Aqemia in July 2026, nominating an additional target and making Aqemia eligible for up to $140 million in upfront and milestone payments. The collaboration spans hit identification through development-candidate selection.

What this tells us: Platform credibility is built through repeatable partner decisions, not funding announcements. Sanofi’s expansion suggests Aqemia’s designs are meeting the quality threshold needed for continued pharmaceutical investment. The next test is progression beyond discovery into development.

Owkin applies AI to patient data, digital pathology, spatial biology and multimodal biomedical datasets to identify disease biology, biomarkers and therapeutic targets.

Focus: Owkin’s K Pro platform helps pharmaceutical partners apply AI models to patient and multimodal datasets without centralising sensitive information. It focuses on target selection, biomarker discovery and patient stratification.

2026 development: Boehringer Ingelheim became the third major pharmaceutical company to adopt K Pro in 2026, joining Sanofi and AstraZeneca. Owkin has also announced a cardiovascular risk stratification collaboration with Amgen.

What this tells us: AI drug discovery is not only about designing molecules. It is also about improving the upstream decisions that determine whether a programme is worth funding. Owkin’s adoption by three major pharmaceutical companies suggests patient-data-driven discovery is becoming practical pharmaceutical R&D infrastructure.

Iktos combines generative AI for molecular design with AI-orchestrated robotics and automated chemistry.

Focus: Iktos generates molecular candidates computationally, then connects design to automated synthesis and biological testing. Experimental results feed back into the model, creating a faster design, synthesise and test cycle.

2026 development: Servier announced a multi-programme partnership with Iktos in 2026, with potential value exceeding €1 billion. Iktos will generate candidates for Servier to advance into preclinical and clinical development. Iktos also began an oncology collaboration with Pierre Fabre in January 2026.

What this tells us: A promising in silico molecule has limited value if it cannot be synthesised and tested quickly enough to inform the next design cycle. Iktos is testing whether combining generative chemistry with laboratory automation can close that loop.

Healx is a Cambridge-based AI-native biotech using its Healnet platform to identify repurposing opportunities and combination therapies for rare diseases.

Focus: Healnet integrates biomedical data, disease-specific evidence and network analysis to identify combinations of existing or development-stage compounds that may address rare disease mechanisms.

2026 development: Healx dosed the first patient in a Phase 1/2 trial of HLX-4310, an oral HDAC and mTOR inhibitor combination, in relapsed or refractory sarcoma with a focus on osteosarcoma. The company also has partnerships with Sanofi and Boehringer Ingelheim.

What this tells us: Healx shows that AI can support the path from biological data to a company-owned clinical asset. Its rare-disease focus matters because repurposing and combination biology can offer a more tractable route to the clinic than de novo drug design.

Cradle is an Amsterdam- and Zurich-based AI protein engineering company. Its platform helps scientists design, optimise and prioritise protein candidates using experimental data generated throughout discovery.

Focus: Cradle applies generative AI and active learning to protein engineering. Scientists use it to design antibody candidates, optimise multiple properties in parallel and reduce wet-lab iterations.

2026 development: Bayer entered a three-year strategic collaboration with Cradle in January 2026 across antibody lead generation and optimisation. Lundbeck began using the platform in June 2026 across two CNS antibody programmes, and Hansa Biopharma announced a partnership in October 2026 across its autoimmune disease pipeline. Cradle reports more than 50 projects and adoption by six of the top 25 pharmaceutical companies.

What this tells us: Cradle shows AI becoming embedded in day-to-day pharmaceutical discovery rather than remaining a standalone platform. Its value depends on whether AI-guided protein design reduces experimental cycles while maintaining developability, safety and biological function.

ENPICOM is a ’s-Hertogenbosch-based bioinformatics and AI company focused on biologics discovery. Its platform integrates antibody discovery data, automated analysis and machine learning to move scientists from sequencing data to candidate selection.

Focus: ENPICOM applies AI and computational science to antibody discovery workflows, including NGS analysis, clone selection, candidate prioritisation and data integration.

2026 development: Evolved Therapeutics selected the ENPICOM Platform in September 2026 to accelerate antibody discovery campaigns. ENPICOM is also working with Imuno Therapeutics on TACIDO, an end-to-end AI pipeline for tumour-targeted antibody discovery.

What this tells us: Not every AI drug discovery company designs molecules from scratch. ENPICOM represents the data infrastructure layer: systems that turn biological experiments into decisions scientists can act on. Its relevance is especially strong in biologics, where discovery generates large volumes of sequencing and screening data.

Turbine is a Budapest-based company using AI-based simulated cell technology to model tumour biology and support preclinical discovery decisions.

Focus: Turbine builds simulated cell models to help researchers understand disease mechanisms, predict drug responses and identify potential therapeutic targets.

2026 development: Turbine has worked with pharmaceutical companies including Bayer and is developing its own pipeline, including a target associated with PARP inhibitor resistance. Industry coverage in 2026 positions the company as part of Hungary’s expanding digital drug discovery ecosystem.

What this tells us: Turbine addresses a different question from molecular design companies. Rather than asking whether AI can generate a better molecule, it asks whether AI can improve biological decisions before a molecule is synthesised or tested.

Antiverse is a Cardiff-based AI antibody discovery company using a lab-in-the-loop approach to design biologics against difficult targets, including GPCRs, ion channels and other complex membrane proteins.

Focus: Antiverse combines generative AI, proprietary antibody datasets and computational modelling with in-house laboratory testing. Designed antibodies are tested internally before being progressed or redesigned.

2026 development: Antiverse raised a $9.3 million Series A in March 2026 to scale its platform and advance internal antibody programmes towards in vivo efficacy studies. It has also announced a Cystic Fibrosis Foundation collaboration and a GPCR-targeted antibody collaboration with Nxera Pharma.

What this tells us: Antiverse is not yet a clinical validation story. Its evidence is partner adoption, preclinical progression and proprietary experimental capability. Its significance lies in whether AI can make difficult target classes accessible to biologics programmes.

Ardigen is a Kraków-based computational biology company applying AI and bioinformatics to drug discovery, with focus on immuno-oncology, precision medicine and synergistic target combinations for complex biologics.

Focus: Ardigen develops AI-enabled tools for target biology, biomarker discovery, patient stratification and combination target identification.

2026 development: Ardigen announced a collaboration with VERAXA Biotech in July 2026 to develop AI-enabled tools for selecting synergistic cancer target pairs across VERAXA’s BiTAC pipeline of T-cell engagers and future antibody-drug conjugates.

What this tells us: As biologics become more complex, the upstream problem becomes harder. For bispecifics, T-cell engagers and antibody-drug conjugates, the challenge is not only designing a molecule but identifying target combinations that are biologically synergistic rather than merely co-expressed.

Yes, but clinical entry and clinical validation are different things.

Most programmes involve AI-generated hypotheses, human scientific judgement, experimental validation and conventional medicinal chemistry. The extent to which AI influenced the key decision varies considerably and is often not disclosed in enough detail to allow clean comparisons.

With that caveat, industry reporting points to more than 170 AI-discovered programmes in clinical development globally. Isomorphic Labs is one of Europe’s most closely watched companies because its AI-first design engine is being scaled towards clinical development.

Insilico Medicine’s Rentosertib provides useful global context, although the company is not European-headquartered. Its programme entered a Phase 3 trial for idiopathic pulmonary fibrosis in 2026, making it one of the most advanced AI-designed candidates in clinical development.

The honest summary is that AI-discovered programmes are reaching clinical trials faster than many expected five years ago. Whether they will achieve materially better clinical success rates than conventionally discovered drugs remains unproven.

At Panda International, we connect life sciences companies with the specialist talent they need to move innovation forward.

Looking to strengthen your team in AI-driven drug discovery? Get in touch with our team.